Dalbavancin

Rev Esp Quimioter. 2021 Sep;34 Suppl 1:26-28. doi: 10.37201/req/s01.07.2021. Epub 2021 Sep 30.

ABSTRACT

Dalbavancin is a long-acting antimicrobial agent with an excellent in vitro activity against Gram-positive pathogens, including staphylococcal biofilms. The unusually long terminal half-life ranging from 149 to 250 hours in human subjects, allows a weekly dose. Currently is indicated in acute bacterial skin and skin structure infections (ABSSSIs), but in real-life clinical practice it has already been used successfully and safely in other infections, especially as consolidation therapy.

PMID:34598419 | DOI:10.37201/req/s01.07.2021